Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders

被引:6
作者
Altés, A
López, R
Martino, R
Martinez, C
Cabezudo, E
Muñoz, L
Santamaría, A
Perea, G
Briones, J
Salar, A
Sureda, A
Brunet, S
Madoz, P
Sierra, J
机构
[1] Hosp Santa Creu & Sant Pau, Clin Hematol Div, Barcelona 08025, Spain
[2] Hosp Santa Creu & Sant Pau, Hemotherapy Serv, Barcelona 08025, Spain
[3] Autonomous Univ Barcelona, Inst Canc Res, Barcelona, Spain
关键词
PBPC mobilization; lymphoma; chemotherapy;
D O I
10.1038/sj.bmt.1702476
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We have explored the efficacy of salvage chemotherapy combination, IAPVP-16 (ifosfamide 5 g/m(2) on day 1; VP-16 100 mg/m(2) on days 1-3; ara-C 1.2 g/m(2)/12 h on days 1 and 2; methylprednisolone 80 mg/m(2) on days 1-5) plus G-CSF for PBPC mobilization, This protocol was used in 45 patients with relapsed or refractory lymphoproliferative diseases who underwent 85 leukaphereses, Tn 41 patients >2 x 10(6)/kg CD34(+) cells were obtained after a median of two procedures. The median number of CD34(+) cells harvested was 3.2 x 10(6)/kg per apheresis and 8.4 x 10(6)/kg per patient. Seven of 10 patients who had failed previous mobilization attempts achieved more than 2 x 10(6) CD34(+) cells/kg in a maximum of three aphereses, A history of previous mobilization failure and a low platelet count (<150 x 10(9)/1) negatively influenced the CD34(+) cell yield in univariate and multivariate analyses. A good correlation was found between the circulating CD34(+) cells/mu l and the CD34(+) cells and CFU-GM in the leukaphereses products (r = 0.93 and r = 0.73, P < 0.001), and greater than or equal to 17 CD34(+) cells/mu l predicted the achievement of >2 x 10(6)/kg CD34(+) cells in a single leukapheresis in more than 90% of cases. IAPVP-16 plus G-CSF may be specially indicated in tandem transplantations or CD34(+) selection and in patients who have failed previous mobilization attempts.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 24 条
[21]   The biology and clinical uses of blood stem cells [J].
To, LB ;
Haylock, D ;
Simmons, PJ ;
Juttner, CA .
BLOOD, 1997, 89 (07) :2233-2258
[22]  
TO LB, 1992, BONE MARROW TRANSPL, V9, P227
[23]   Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma [J].
Watts, MJ ;
Sullivan, AM ;
Jamieson, E ;
Pearce, R ;
Fielding, A ;
Devereux, S ;
Goldstone, AH ;
Linch, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :535-546
[24]   Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients [J].
Weaver, CH ;
Schwartzberg, LS ;
Birch, R ;
Greco, FA ;
Rhinehart, S ;
Hainsworth, J ;
Beeker, T ;
Price, H ;
Geier, L ;
Foster, J ;
West, J ;
Hazelton, B ;
Buckner, CD .
TRANSFUSION, 1997, 37 (09) :896-903